Temporal trends in mortality, heart failure hospitalization, and stroke in heart failure patients with and without atrial fibrillation: A nationwide study from 1997-2018 on 152,059 patients

Abstract

Background Given the many advances in treating heart failure (HF) and atrial fibrillation (AF) separately over the past decades, it remains unclear how the prognosis of patients diagnosed with both conditions has changed over time. We aimed to investigate the temporal trends in clinical outcomes from 1997 to 2018 in patients diagnosed with both HF and AF.

Methods From Danish nationwide registries, we identified 152,059 patients with a first-time HF-diagnosis from 1997 to 2018. Patients were grouped according to year of new-onset HF and AF-status: Prevalent AF (n=34,734), New-onset HF (n=12,691), and No AF (n=104,634). Outcomes of interest were the five-year risk of all-cause mortality, HF-hospitalization, and stroke.

Results Between 1997 and 2018, the proportion of patients with prevalent or new-onset AF increased from 24.7% (n=9256) to 35.8% (n=14,970). The five-year risk of all-cause mortality decreased from 69.1% (95% CI): 67.9%-70.2%) to 51.3% (49.9%-52.7%), 62.3% (60.5%-64.4%) to 43.0% (40.5%-45.5%), and 61.9% (61.3%-62.4%) to 36.7% (35.9%-37.6%) for the prevalent AF, new-onset AF, and no AF group, respectively. Minimal changes were observed in the risk of HF-hospitalization. The five-year risk of stroke decreased from 8.5% (7.8%-9.1%) to 5.0% (4.4%-5.5%) in the prevalent AF group, 8.2% (7.2%-9.2%) to 4.6% (3.7%-5.5%) in the new-onset AF group, and 6.3% (6.1%-6.6%) to 4.9% (4.6%-5.3%) in the no AF group. Simultaneously, patients prescribed anticoagulant therapy within 90 days after HF-onset increased from 42.7% to 93.1% in patients with prevalent AF and 41.9% to 92.5% in patients with new-onset AF.

Conclusion From 1997 to 2018, we observed an increase in patients with HF and coexisting AF. Mortality and stroke risk decreased across all patient groups regardless of AF-status. Anticoagulation therapy increased, and stroke risk in patients with HF and AF was reduced to similar levels as HF patients without AF at the end of the study period.

What is new?

• In patients with heart failure, an increasing proportion had concomitant atrial fibrillation in 2018 versus 1997.

• The mortality- and stroke risk decreased for all patients with heart failure over the past two decades, also for patients with coexisting atrial fibrillation, and more patients received guideline-recommended therapy in 2018 versus in 1997.

What are the clinical implications?

• The increasing trend of patients with heart failure and coexisting atrial fibrillation necessitates a better understanding of the coexistence of these two conditions, of which this study provides insight into the evolving prognosis and management landscape of individuals with both heart failure and atrial fibrillation over the past two decades.

• Download figure
• Open in new tab

Competing Interest Statement

M.E.M. reports grants from CARDIO-HGH Foundation, Herlev-Gentofte University Hospital and Danish Cardiovascular Academy, unrelated to the submitted work. C.H.G reports personal fees from lectures honorarium from Astra Zeneca, unrelated to the submitted work. J.B.O reports speaker honorarium or consultancy fees from Bayer, Bristol-Myers Squibb, and Pfizer, unrelated to the submitted work. E.F. declares an independent research grant related to valvular heart disease and endocarditis from the Novo Nordisk Foundation and the Danish Heart Association, unrelated to submitted work. L.Ø. declares an independent research grant related to research in mitral valve regurgitation from the Novo Nordisk Foundation, unrelated to the submitted work. L.K reports speaker honorarium from Novo Nordisk, AstraZeneca, Novartis, and Boehringer Ingelheim, unrelated to the submitted work. M.S reports lecture fees from Novartis, Boehringer-Ingelheim, Astra Zeneca and Novo Nordisk, unrelated to the submitted work. The other authors report no conflicts.

Funding Statement

Hospital grants, Department of cardiology, Herlev-Gentofte Hospital

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Data for this study were approved for use by Statistics Denmark. Ethical approval was not necessary according to the Danish regulations regarding observational retrospective register-based studies.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes